Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Hydroxyurea
Drug ID BADD_D01110
Description An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
Indications and Usage For management of melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary and Sickle-cell anemia.
Marketing Status approved
ATC Code L01XX05
DrugBank ID DB01005
KEGG ID D00341
MeSH ID D006918
PubChem ID 3657
TTD Drug ID D07CWD
NDC Product Code 0904-6939; 35369-0006; 49452-3650; 55154-7143; 61269-403; 68084-284; 70518-3615; 51927-0072; 0555-0882; 55154-3554; 69315-164; 38779-1354; 42291-321; 71770-105; 49884-724; 17337-0023; 0003-6335; 0003-6337; 60429-265; 61269-835; 70518-0916; 55512-0003; 61269-402; 71770-120; 0003-0830; 51552-0851; 62049-135; 0003-6336; 61269-404; 10135-702; 71052-323; 17337-0022
UNII X6Q56QN5QC
Synonyms Hydroxyurea | Hydroxycarbamid | Oncocarbide | Hydrea
Chemical Information
Molecular Formula CH4N2O2
CAS Registry Number 127-07-1
SMILES C(=O)(N)NO
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Central nervous system lymphoma18.04.04.013; 17.02.10.028; 16.20.01.005; 01.12.01.0050.000112%-
Concomitant disease aggravated08.01.03.0630.000280%-
Hypergammaglobulinaemia benign monoclonal16.23.01.004; 01.14.01.0040.000112%-
Metastases to lymph nodes16.22.02.006; 01.09.01.0150.000112%-
Normal newborn18.08.06.0010.000302%-
Scleroderma-like reaction23.03.02.019; 15.06.01.018; 10.04.07.0050.000112%-
Splenic haematoma12.01.17.019; 24.07.01.079; 01.09.02.0140.000168%-
Squamous cell carcinoma of the oral cavity16.13.07.006; 07.21.07.0090.000112%-
Squamous cell carcinoma of the tongue16.13.07.007; 07.21.07.0100.000112%-
Vitamin B1 deficiency14.12.02.0120.000381%-
Concomitant disease progression08.01.03.0640.000112%-
Live birth18.08.02.0070.000224%-
Blast crisis in myelogenous leukaemia16.01.08.002; 01.10.08.0020.000112%-
Gastric antral vascular ectasia24.03.03.028; 07.15.04.0030.000112%-
Metastases to meninges17.02.10.012; 16.22.02.0030.000112%-
Acute chest syndrome24.03.08.006; 22.06.03.004; 01.04.02.0040.000168%-
Pachymeningitis17.06.03.0040.000112%-
Breast cancer metastatic21.05.01.016; 16.10.01.0080.000112%-
Gastric varices haemorrhage24.07.02.044; 09.01.06.014; 07.12.01.0050.000112%-
Nephrogenic anaemia01.03.04.001; 20.01.01.0070.000112%-
Thalamus haemorrhage24.07.04.033; 17.08.01.0620.000168%-
Acute myeloid leukaemia recurrent16.01.05.004; 01.10.05.0040.000112%-
Leukaemia recurrent16.01.03.005; 01.10.03.0050.000112%-
Acute lymphocytic leukaemia recurrent16.01.01.003; 01.10.01.0030.000112%-
Gastric fistula12.02.03.018; 07.11.05.0110.000112%
Internal haemorrhage24.07.01.0720.000112%-
Primary myelofibrosis16.21.03.008; 01.13.03.0080.000504%-
Acute erythroid leukaemia16.01.05.006; 01.10.05.0060.000168%-
Acute megakaryocytic leukaemia16.01.05.007; 01.10.05.007---
Blood loss anaemia24.07.01.088; 01.03.02.0180.000168%-
The 12th Page    First    Pre   12 13    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene